{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:56:58Z","timestamp":1792112218371,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001700","name":"The Japanese Ministry of Education, Culture, Sports, Science, and Technology","doi-asserted-by":"crossref","award":["#22H03242"],"award-info":[{"award-number":["#22H03242"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"The Japanese Ministry of Education, Culture, Sports, Science, and Technology","doi-asserted-by":"crossref","award":["22KK0136"],"award-info":[{"award-number":["22KK0136"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Japan Agency for Medical Research and Development, Practical Research Project for Rare\/Intractable Diseases","award":["JP23ek0109512h0003"],"award-info":[{"award-number":["JP23ek0109512h0003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10384-025-01179-2","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T06:51:21Z","timestamp":1741157481000},"page":"378-386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Study protocol for a prospective natural history registry investigating the relationships between inflammatory markers and disease progression in retinitis pigmentosa: the RP-PRIMARY study"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3761-1732","authenticated-orcid":false,"given":"Yusuke","family":"Murakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Hisai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakurako","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohta","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akie","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyuka","family":"Miyahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kobayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Mawatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Ishizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Kaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh-Hei","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"1179_CR1","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","volume":"368","author":"DT Hartong","year":"2006","unstructured":"Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368:1795\u2013809.","journal-title":"Lancet"},{"key":"1179_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10384-018-0623-4","volume":"63","author":"Y Morizane","year":"2019","unstructured":"Morizane Y, Morimoto N, Fujiwara A, Kawasaki R, Yamashita H, Ogura Y, et al. Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J Ophthalmol. 2019;63:26\u201333.","journal-title":"Jpn J Ophthalmol"},{"key":"1179_CR3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s10384-023-00986-9","volume":"67","author":"R Matoba","year":"2023","unstructured":"Matoba R, Morimoto N, Kawasaki R, Fujiwara M, Kanenaga K, Yamashita H, et al. A nationwide survey of newly certified visually impaired individuals in Japan for the fiscal year 2019: impact of the revision of criteria for visual impairment certification. Jpn J Ophthalmol. 2023;67:346\u201352.","journal-title":"Jpn J Ophthalmol"},{"key":"1179_CR4","doi-asserted-by":"publisher","first-page":"11300","DOI":"10.1073\/pnas.0604056103","volume":"103","author":"K Komeima","year":"2006","unstructured":"Komeima K, Rogers BS, Lu L, Campochiaro PA. Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natl Acad Sci U S A. 2006;103:11300\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1179_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.preteyeres.2017.08.004","volume":"62","author":"PA Campochiaro","year":"2018","unstructured":"Campochiaro PA, Mir TA. The mechanism of cone cell death in retinitis pigmentosa. Prog Retin Eye Res. 2018;62:24\u201337.","journal-title":"Prog Retin Eye Res"},{"key":"1179_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nn.2234","volume":"12","author":"C Punzo","year":"2009","unstructured":"Punzo C, Kornacker K, Cepko CL. Stimulation of the insulin\/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. Nat Neurosci. 2009;12:44\u201352.","journal-title":"Nat Neurosci"},{"key":"1179_CR7","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.cell.2015.03.023","volume":"161","author":"N Ait-Ali","year":"2015","unstructured":"Ait-Ali N, Fridlich R, Millet-Puel G, Clerin E, Delalande F, Jaillard C, et al. Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis. Cell. 2015;161:817\u201332.","journal-title":"Cell"},{"key":"1179_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ophtha.2012.07.006","volume":"120","author":"N Yoshida","year":"2013","unstructured":"Yoshida N, Ikeda Y, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, et al. Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology. 2013;120:100\u20135.","journal-title":"Ophthalmology"},{"key":"1179_CR9","doi-asserted-by":"publisher","first-page":"10140","DOI":"10.1073\/pnas.1901787116","volume":"116","author":"SK Wang","year":"2019","unstructured":"Wang SK, Xue Y, Rana P, Hong CM, Cepko CL. Soluble CX3CL1 gene therapy improves cone survival and function in mouse models of retinitis pigmentosa. Proc Natl Acad Sci U S A. 2019;116:10140\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1179_CR10","doi-asserted-by":"publisher","first-page":"100778","DOI":"10.1016\/j.preteyeres.2019.100778","volume":"74","author":"Y Murakami","year":"2020","unstructured":"Murakami Y, Ishikawa K, Nakao S, Sonoda KH. Innate immune response in retinal homeostasis and inflammatory disorders. Prog Retin Eye Res. 2020;74:100778.","journal-title":"Prog Retin Eye Res"},{"key":"1179_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849\u201360.","journal-title":"Lancet"},{"key":"1179_CR12","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.ophtha.2024.02.023","volume":"131","author":"BL Lam","year":"2024","unstructured":"Lam BL, Pennesi ME, Kay CN, Panda S, Gow JA, Zhao G, et al. Assessment of visual function with cotoretigene toliparvovec in X-linked retinitis pigmentosa in the randomized XIRIUS phase 2\/3 study. Ophthalmology. 2024;131:1083\u201393.","journal-title":"Ophthalmology"},{"key":"1179_CR13","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41591-021-01351-4","volume":"27","author":"JA Sahel","year":"2021","unstructured":"Sahel JA, Boulanger-Scemama E, Pagot C, Arleo A, Galluppi F, Martel JN, et al. Partial recovery of visual function in a blind patient after optogenetic therapy. Nat Med. 2021;27:1223\u20139.","journal-title":"Nat Med"},{"key":"1179_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0140-6736(14)61376-3","volume":"385","author":"SD Schwartz","year":"2015","unstructured":"Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt\u2019s macular dystrophy: follow-up of two open-label phase 1\/2 studies. Lancet. 2015;385:509\u201316.","journal-title":"Lancet"},{"key":"1179_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13287-017-0661-8","volume":"8","author":"Y Liu","year":"2017","unstructured":"Liu Y, Chen SJ, Li SY, Qu LH, Meng XH, Wang Y, et al. Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients. Stem Cell Res Ther. 2017;8:209.","journal-title":"Stem Cell Res Ther"},{"key":"1179_CR16","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.stem.2023.11.004","volume":"30","author":"Y Hirami","year":"2023","unstructured":"Hirami Y, Mandai M, Sugita S, Maeda A, Maeda T, Yamamoto M, et al. Safety and stable survival of stem-cell-derived retinal organoid for 2 years in patients with retinitis pigmentosa. Cell Stem Cell. 2023;30:1585\u201396. e6.","journal-title":"Cell Stem Cell"},{"key":"1179_CR17","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s00417-023-05986-6","volume":"261","author":"AD Dave","year":"2023","unstructured":"Dave AD, Chen KG, Chiang TT, Singaravelu J, Alvarez JA, Wong WT, et al. Oral minocycline for the treatment of retinitis pigmentosa-associated cystoid macular edema: results of a phase I\/II clinical trial. Graefes Arch Clin Exp Ophthalmol. 2023;261:2209\u201320.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1179_CR18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","volume":"126","author":"AM Maguire","year":"2019","unstructured":"Maguire AM, Russell S, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology. 2019;126:1273\u201385.","journal-title":"Ophthalmology"},{"key":"1179_CR19","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","volume":"390","author":"EA Pierce","year":"2024","unstructured":"Pierce EA, Aleman TS, Jayasundera KT, Ashimatey BS, Kim K, Rashid A, et al. Gene editing for CEP290-associated retinal degeneration. N Engl J Med. 2024;390:1972\u201384.","journal-title":"N Engl J Med"},{"key":"1179_CR20","doi-asserted-by":"publisher","first-page":"368rv6","DOI":"10.1126\/scitranslmed.aaf2838","volume":"8","author":"HP Scholl","year":"2016","unstructured":"Scholl HP, Strauss RW, Singh MS, Dalkara D, Roska B, Picaud S, et al. Emerging therapies for inherited retinal degeneration. Sci Transl Med. 2016;8:368rv6.","journal-title":"Sci Transl Med"},{"key":"1179_CR21","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/j.ymthe.2021.04.024","volume":"29","author":"K Dulla","year":"2021","unstructured":"Dulla K, Slijkerman R, van Diepen HC, Albert S, Dona M, Beumer W, et al. Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations. Mol Ther. 2021;29:2441\u201355.","journal-title":"Mol Ther"},{"key":"1179_CR22","doi-asserted-by":"publisher","first-page":"pgac003","DOI":"10.1093\/pnasnexus\/pgac003","volume":"1","author":"J Funatsu","year":"2022","unstructured":"Funatsu J, Murakami Y, Shimokawa S, Nakatake S, Fujiwara K, Okita A, et al. Circulating inflammatory monocytes oppose microglia and contribute to cone cell death in retinitis pigmentosa. PNAS Nexus. 2022;1:pgac003.","journal-title":"PNAS Nexus"},{"key":"1179_CR23","doi-asserted-by":"publisher","first-page":"e0226097","DOI":"10.1371\/journal.pone.0226097","volume":"14","author":"J Funatsu","year":"2019","unstructured":"Funatsu J, Murakami Y, Nakatake S, Akiyama M, Fujiwara K, Shimokawa S, et al. Direct comparison of retinal structure and function in retinitis pigmentosa by co-registering microperimetry and optical coherence tomography. PLoS ONE. 2019;14:e0226097.","journal-title":"PLoS ONE"},{"key":"1179_CR24","doi-asserted-by":"publisher","first-page":"8070","DOI":"10.1038\/s41598-018-26231-9","volume":"8","author":"K Fujiwara","year":"2018","unstructured":"Fujiwara K, Ikeda Y, Murakami Y, Tachibana T, Funatsu J, Koyanagi Y, et al. Assessment of central visual function in patients with retinitis pigmentosa. Sci Rep. 2018;8:8070.","journal-title":"Sci Rep"},{"key":"1179_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1167\/tvst.12.6.4","volume":"12","author":"LJ Taylor","year":"2023","unstructured":"Taylor LJ, Josan AS, Jolly JK, MacLaren RE. Microperimetry as an outcome measure in RPGR-associated retinitis pigmentosa clinical trials. Transl Vis Sci Technol. 2023;12:4.","journal-title":"Transl Vis Sci Technol"},{"key":"1179_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamaophthalmol.2022.6254","volume":"141","author":"L von Krusenstiern","year":"2023","unstructured":"von Krusenstiern L, Liu J, Liao E, Gow JA, Chen G, Ong T, et al. Changes in retinal sensitivity associated with cotoretigene toliparvovec in X-linked retinitis pigmentosa with RPGR gene variations. JAMA Ophthalmol. 2023;141:275\u201383.","journal-title":"JAMA Ophthalmol"},{"key":"1179_CR27","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1136\/jmedgenet-2018-105691","volume":"56","author":"Y Koyanagi","year":"2019","unstructured":"Koyanagi Y, Akiyama M, Nishiguchi KM, Momozawa Y, Kamatani Y, Takata S, et al. Genetic characteristics of retinitis pigmentosa in 1204 Japanese patients. J Med Genet. 2019;56:662\u201370.","journal-title":"J Med Genet"},{"key":"1179_CR28","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1136\/jmg-2023-109750","volume":"61","author":"K Goto","year":"2024","unstructured":"Goto K, Koyanagi Y, Akiyama M, Murakami Y, Fukushima M, Fujiwara K, et al. Disease-specific variant interpretation highlighted the genetic findings in 2325 Japanese patients with retinitis pigmentosa and allied diseases. J Med Genet. 2024;61:613\u201320.","journal-title":"J Med Genet"},{"key":"1179_CR29","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1136\/bjophthalmol-2012-303005","volume":"97","author":"Y Ikeda","year":"2013","unstructured":"Ikeda Y, Yoshida N, Notomi S, Murakami Y, Hisatomi T, Enaida H, et al. Therapeutic effect of prolonged treatment with topical dorzolamide for cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol. 2013;97:1187\u201391.","journal-title":"Br J Ophthalmol"},{"key":"1179_CR30","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.ophtha.2015.12.009","volume":"123","author":"RW Strauss","year":"2016","unstructured":"Strauss RW, Ho A, Munoz B, Cideciyan AV, Sahel JA, Sunness JS, et al. The natural history of the progression of atrophy secondary to Stargardt disease (ProgStar) studies: design and baseline characteristics: ProgStar Report 1. Ophthalmology. 2016;123:817\u201328.","journal-title":"Ophthalmology"},{"key":"1179_CR31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/bjophthalmol-2018-312064","volume":"103","author":"K Fujinami","year":"2019","unstructured":"Fujinami K, Strauss RW, Chiang JP, Audo IS, Bernstein PS, Birch DG, et al. Detailed genetic characteristics of an international large cohort of patients with Stargardt disease: ProgStar study report 8. Br J Ophthalmol. 2019;103:390\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1179_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ajo.2020.03.020","volume":"216","author":"EM Schonbach","year":"2020","unstructured":"Schonbach EM, Strauss RW, Ibrahim MA, Janes JL, Birch DG, Cideciyan AV, et al. Faster sensitivity loss around dense scotomas than for overall macular sensitivity in Stargardt disease: ProgStar Report 14. Am J Ophthalmol. 2020;216:219\u201325.","journal-title":"Am J Ophthalmol"},{"key":"1179_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ajo.2021.07.013","volume":"233","author":"EM Schonbach","year":"2022","unstructured":"Schonbach EM, Strauss RW, Cattaneo M, Fujinami K, Birch DG, Cideciyan AV, et al. Longitudinal changes of fixation stability and location within 24 months in Stargardt disease: ProgStar Report 16. Am J Ophthalmol. 2022;233:78\u201389.","journal-title":"Am J Ophthalmol"},{"key":"1179_CR34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ajo.2022.08.013","volume":"244","author":"EM Lad","year":"2022","unstructured":"Lad EM, Duncan JL, Liang W, Maguire MG, Ayala AR, Audo I, et al. Baseline microperimetry and OCT in the RUSH2A study: structure-function association and correlation with disease severity. Am J Ophthalmol. 2022;244:98\u2013116.","journal-title":"Am J Ophthalmol"},{"key":"1179_CR35","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/humu.24365","volume":"43","author":"RB Hufnagel","year":"2022","unstructured":"Hufnagel RB, Liang W, Duncan JL, Brewer CC, Audo I, Ayala AR, et al. Tissue-specific genotype-phenotype correlations among USH2A-related disorders in the RUSH2A study. Hum Mutat. 2022;43:613\u201324.","journal-title":"Hum Mutat"},{"key":"1179_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ajo.2023.02.002","volume":"250","author":"JL Duncan","year":"2023","unstructured":"Duncan JL, Cheng P, Maguire MG, Ayala AA, Birch DG, Cheetham JK, et al. Static perimetry in the rate of progression in USH2A-related retinal degeneration (RUSH2A) study: assessment through 2 years. Am J Ophthalmol. 2023;250:103\u201310.","journal-title":"Am J Ophthalmol"},{"key":"1179_CR37","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1002\/jcp.22508","volume":"226","author":"SY Lee","year":"2011","unstructured":"Lee SY, Usui S, Zafar AB, Oveson BC, Jo YJ, Lu L, et al. N-acetylcysteine promotes long-term survival of cones in a model of retinitis pigmentosa. J Cell Physiol. 2011;226:1843\u20139.","journal-title":"J Cell Physiol"},{"key":"1179_CR38","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1172\/JCI132990","volume":"130","author":"PA Campochiaro","year":"2020","unstructured":"Campochiaro PA, Iftikhar M, Hafiz G, Akhlaq A, Tsai G, Wehling D, et al. Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial. J Clin Invest. 2020;130:1527\u201341.","journal-title":"J Clin Invest"},{"key":"1179_CR39","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","volume":"385","author":"DF Garway-Heath","year":"2015","unstructured":"Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385:1295\u2013304.","journal-title":"Lancet"},{"key":"1179_CR40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0014-4835(02)00332-9","volume":"76","author":"N Gupta","year":"2003","unstructured":"Gupta N, Brown KE, Milam AH. Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration. Exp Eye Res. 2003;76:463\u201371.","journal-title":"Exp Eye Res"},{"key":"1179_CR41","doi-asserted-by":"publisher","first-page":"11668","DOI":"10.1038\/s41598-019-48158-5","volume":"9","author":"G Miura","year":"2019","unstructured":"Miura G, Sugawara T, Kawasaki Y, Tatsumi T, Nizawa T, Baba T, et al. Clinical trial to evaluate safety and efficacy of transdermal electrical stimulation on visual functions of patients with retinitis pigmentosa. Sci Rep. 2019;9:11668.","journal-title":"Sci Rep"},{"key":"1179_CR42","doi-asserted-by":"publisher","first-page":"843558","DOI":"10.3389\/fimmu.2022.843558","volume":"13","author":"SK Wang","year":"2022","unstructured":"Wang SK, Cepko CL. Targeting microglia to treat degenerative eye diseases. Front Immunol. 2022;13:843558.","journal-title":"Front Immunol"},{"key":"1179_CR43","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/glia.23016","volume":"64","author":"MK Zabel","year":"2016","unstructured":"Zabel MK, Zhao L, Zhang Y, Gonzalez SR, Ma W, Wang X, et al. Microglial phagocytosis and activation underlying photoreceptor degeneration is regulated by CX3CL1-CX3CR1 signaling in a mouse model of retinitis pigmentosa. Glia. 2016;64:1479\u201391.","journal-title":"Glia"},{"key":"1179_CR44","doi-asserted-by":"publisher","first-page":"e42049","DOI":"10.7554\/eLife.42049","volume":"8","author":"W Ma","year":"2019","unstructured":"Ma W, Silverman SM, Zhao L, Villasmil R, Campos MM, Amaral J, et al. Absence of TGFbeta signaling in retinal microglia induces retinal degeneration and exacerbates choroidal neovascularization. Elife. 2019;8:e42049.","journal-title":"Elife"},{"key":"1179_CR45","first-page":"4360","volume":"130","author":"SK Wang","year":"2020","unstructured":"Wang SK, Xue Y, Cepko CL. Microglia modulation by TGF-beta1 protects cones in mouse models of retinal degeneration. J Clin Invest. 2020;130:4360\u20139.","journal-title":"J Clin Invest"},{"key":"1179_CR46","doi-asserted-by":"publisher","first-page":"E11359","DOI":"10.1073\/pnas.1807123115","volume":"115","author":"EI Paschalis","year":"2018","unstructured":"Paschalis EI, Lei F, Zhou C, Kapoulea V, Dana R, Chodosh J, et al. Permanent neuroglial remodeling of the retina following infiltration of CSF1R inhibition-resistant peripheral monocytes. Proc Natl Acad Sci U S A. 2018;115:E11359\u201368.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1179_CR47","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1111\/aos.13502","volume":"96","author":"Y Murakami","year":"2018","unstructured":"Murakami Y, Ikeda Y, Nakatake S, Fujiwara K, Tachibana T, Yoshida N, et al. C-Reactive protein and progression of vision loss in retinitis pigmentosa. Acta Ophthalmol. 2018;96:e174\u20139.","journal-title":"Acta Ophthalmol"},{"key":"1179_CR48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1167\/iovs.61.11.30","volume":"61","author":"A Okita","year":"2020","unstructured":"Okita A, Murakami Y, Shimokawa S, Funatsu J, Fujiwara K, Nakatake S, et al. Changes of serum inflammatory molecules and their relationships with visual function in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2020;61:30.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1179_CR49","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10384-022-00941-0","volume":"66","author":"M Miyake","year":"2022","unstructured":"Miyake M, Akiyama M, Kashiwagi K, Sakamoto T, Oshika T. Japan ocular imaging registry: a national ophthalmology real-world database. Jpn J Ophthalmol. 2022;66:499\u2013503.","journal-title":"Jpn J Ophthalmol"},{"key":"1179_CR50","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1016\/j.ajo.2020.01.028","volume":"214","author":"S Patel","year":"2020","unstructured":"Patel S, Sternberg P. Jr. real-world data in ophthalmology. Am J Ophthalmol. 2020;214:A1-2.","journal-title":"Am J Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01179-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01179-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01179-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:01:45Z","timestamp":1748584905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01179-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1179"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01179-2","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y. Murakami, Patents planned, issued or pending (Pitavastatin encapsulated nanoparticle medicine for retinitis pigmentosa), Receipt of equipment, materials, drugs, medical writing, gifts or other services (SENTAN\u00a0Pharma Co. Ltd.); T. Hisai, None; S. Shimokawa, None; M. Fukushima, None; K. Fujiwara, None; A. Hirata, None; A. Takada, None; F. Miyahara, None; N. Nakashima, None; Y. Kobayakawa, None; M. Arima, None; G. Mawatari, None; M. Ishizu, None; T. Kaida, None; K. Miyata, None; Y. Ikeda, None; K. Sonoda, None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}